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http://dx.doi.org/10.1016/j.kjms.201Abstract Neonatal alloimmune thrombocytopenia (NAIT) is a clinical syndrome that resembles
hemolytic disease of the newborn, affecting the platelets only. The thrombocytopenia results
from the maternal alloantibodies reacting with specific human platelet antigens (HPAs) on
the fetal platelets. Forty-four maternal plasma samples were screened for platelet alloanti-
bodies using qualitative solid phase enzyme-linked immunosorbent assay (ELISA) commercial
kit (LIFECODES Pakplus, Hologic Gen-Probe GTI Diagnostics, Waukesha, WI, USA), and both
the maternal and the corresponding cord blood samples were genotyped (LIFECODES Thrombo-
Type, Hologic Gen-Probe GTI Diagnostics, Waukesha, WI, USA). HPA genotyping results corre-
lated with the genetic frequencies in the Taiwan population. A total of 34 newborns (77.3%)
had partial HPA genotyping mismatches with the corresponding mothers. The most common par-
tial mismatches between mothers and neonates in HPA genotypes were 13 (29.5%) in both HPA-
3b and HPA-15a, followed by 12 (27.3%) in HPA-15b, and 8 (18.2%) in HPA-3a. The frequencies of
homozygotic mother with heterozygotic neonate were 15.9% in both HPA-3a and HPA-15b, 9.1%ave no conflicts of interest relevant to this article.
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Data are presented as n (%).in HPA-15a, 6.8% in HPA-3b, and 2.3% in both HPA-2a and HPA-6a. In this study, maternal HPA
antibodies were found in five samples, whereas HLA class I antibodies were found in seven
maternal plasma samples from the antibody screen. The results from this study have demon-
strated that HPA mismatch is not the main cause for the production of HPA alloantibodies.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Neonatal alloimmune thrombocytopenia (NAIT) is a clinical
syndrome that resembles hemolytic disease of the newborn
affecting the platelets only. The thrombocytopenia results
fromthematernal alloantibodies reactingwith specifichuman
platelet antigens (HPAs) on the fetal platelets that are
paternally inherited.Theantiplateletantibodiesbelong tothe
class of immunoglobulin G antibodies, which are small enough
to cross the placenta anddestroy the fetal platelets [1,2]. The
presence of these platelet alloantibodies may cause severe
thrombocytopenia in fetuses and newborns, and the most
serious cases can result in intracranial hemorrhage (ICH), with
a reported mortality rate estimated between 10% and
20% [3,4].
NAIT, a rare hematologic disorder, presents in 1 of 800 to
1 of 1000 unselected Caucasian newborns, and it is estimated
that half of these cases occur in first pregnancies [2e6]. In
Caucasians, the HPA-1a alloantigen is the most frequently
occurring antigen that is implicated in NAIT, followed by
HPA-5b [7e9]. However, in the Japanese population, anti-
bodies to HPA-4b are most frequently involved in NAIT [10].
In Taiwan, NAIT caused by human platelet alloantibodies is
uncommon, with only a small number of reported cases. Two
cases of severe thrombocytopenia resulting from HPA-3a
were reported in 1995 [11].
According to the previous research in blood donors, the
gene frequencies of HPA-1to HPA-6 and HPA-15 were similar
to those of the Chinese population, but differed from the
Caucasian population. For example, the gene frequencies
are 99.7% for HPA-1a, 96% for HPA-2a, 99.8% for HPA-4a,
and 98.5% for HPA-5a, but the gene frequencies of HPA-3a
and HPA-15a are 57.5% and 53.2%, respectively [12e15].
Almost half of the people lack HPA-3a and HPA-15a, which
may lead to the likelihood of immunization and antibody
formation, but only a few antibodies are detected
clinically.d blood type of 44 mothers, an







AB 7 (15.9)Nevertheless, studies on the HPA alloantibody and the
genetic difference between pregnant women and their
newborns in Taiwan are rare. Therefore, the aim of this
study was to investigate the genetic difference of HPAs
between the mothers and their newborns, and also to
detect maternal alloantibodies against fetal HPAs.
Methods
Specimen collection
Forty-four healthy pregnant women and their newborns
without thrombocytopenia (Table 1) were enrolled in this
study, which was performed in the Taoyuan Armed Forces
General Hospital after approval by the ethics committee.
Maternal peripheral blood samples withdrawn during the
28the36th week of gestation or 24 hours after delivery were
collected for platelet antibody identification, DNA extrac-
tion, and HPA genotyping. Cord blood samples were
collected for DNA extraction and HPA genotyping. All sam-
ples were stored in a nondefrosting freezer at e20C or
below prior to use.
DNA extraction and HPA genotyping
Maternal whole blood and neonatal cord blood were
collected with an EDTA tube. Genomic DNA was isolated
from the buffy coat by commercial DNA extraction kit using
200 mL sample (QIAamp DNA Blood Mini Kit, QIAGEN GmbH,
Hilden, Germany). Extracted DNA was resuspended in
10 mM Tris, pH 8.0-9.0 with 260/280 nm ratio between 1.60
and 1.90.
Genotyping of the human platelet system of mothers and
newborns was carried out by polymerase chain reaction
(PCR) with sequence-specific primer using a commercially
available kit (LIFECODES ThromboType, Hologic Gen-Probe
GTI Diagnostics, Waukesha, WI, USA), in which 400 ng
genomic DNA was mixed with PCR Master Mix and Taqd number of mothers with HLA and HPA antibodies.




3 (6.8) 3 (6.8)
3 (6.8) 1 (2.3)
1 (2.3) 1 (2.3)
2 (4.5) 3 (6.8)
2 (4.5) 1 (2.3)
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Table 2 HPA genotyping and mismatch frequencies of












HPA-1a 100.0 100.0 0 (0.0) 0 (0.0)
HPA-1b 0.0 0.0 0 (0.0) 0 (0.0)
HPA-2a 95.5 95.5 0 (0.0) 1 (2.3)
HPA-2b 4.5 4.5 4 (9.1) 0 (0.0)
HPA-3a 62.5 59.1 8 (18.2) 7 (15.9)
HPA-3b 37.5 40.9 13 (29.5) 3 (6.8)
HPA-4a 100.0 100.0 0 (0.0) 0 (0.0)
HPA-4b 0.0 0.0 0 (0.0) 0 (0.0)
HPA-5a 96.6 98.9 0 (0.0) 0 (0.0)
HPA-5b 3.4 1.1 2 (4.5) 0 (0.0)
HPA-6a 97.7 97.7 0 (0.0) 1 (2.3)
HPA-6b 2.3 2.3 2 (4.5) 0 (0.0)
HPA-15a 44.3 50.0 13 (29.5) 4 (9.1)
HPA-15b 55.7 50.0 12 (27.3) 7 (15.9)
Maternal-neonatal HPA mismatch in Taiwan 27polymerase, and added to each well containing sequence-
specific primers for HPA 1e6, and HPA-15. Internal positive
control primer sets that produced an 85-bp product were
also included in each genotyping run. Negative control
without DNA was also used to check for contamination.
After thermal cycling, PCR products were analyzed by
agarose gel electrophoresis. Finally, three ambiguity sam-
ples were sequenced by the Xinscience Biotech Company in
Taipei, Taiwan.
HPA antibody screening
The maternal plasma samples were screened for
platelet alloantibodies by qualitative solid phase enzyme-
linked immunosorbent assay (ELISA) commercial kit
(LIFECODES Pakplus, Hologic Gen-Probe GTI Diagnostics), in
which 50 mL of diluted serum samples and positive and
negative sera were incubated in wells coated with glyco-
proteins IIb/IIIa, Ib/IX, Ia/IIa, IV, and HLA Class I, respec-
tively. After incubation for 30 minutes at 37C, the wells
were washed three times with 300 mL of wash solution.
Antihuman IgG/A/M conjugate was added for another 30
minutes of incubation at 37C. The wash step was repeated
to remove unbound antibodies. Substrate solution was
added to wells for color development. After adding stop
solution, optical density (OD) was determined with a
microplate reader. Samples with OD equal to or greater
than two times that of the negative control were consid-
ered positive.Results
A total of 88 blood samples were examined from 44 mothers
and their newborns who were healthy and had no throm-
bocytopenia symptom or history prior to participating in
this trial. The average age of the mothers was 30.9 years
(data not shown) and the mean number of previous preg-
nancies was 1.7 (Table 1).
The genotype and gene frequencies of the seven platelet
antigen systems obtained from both 44 pregnant women
and their newborns are shown in Table 2. HPA-1a, HPA-2a,
HPA-4a, HPA-5a, and HPA-6a were present in almost all
samples. HPA-1b and HPA-4b were absent, and HPA-2b,
HPA-5b, and HPA-6b were rare. The frequencies of
maternal/neonatal HPA-3a and HPA-3b were shown to be
62.5%/59.1% and 37.5%/40.9%, respectively, whereas HPA-
15a and HPA-15b were 44.3%/50.0% and 55.7%/50.0%,
respectively.
The genetic variations in HPA-3 and HPA-15 were higher
than those of other HPAs, which correlated with the genetic
frequencies in the Taiwan population. A total of 34 new-
borns (77.3%) had HPA genotyping partial mismatches with
the corresponding mothers. The most common partial
mismatch pairs between mothers and neonates in HPA ge-
notype were 13 (29.5%) in both HPA-3b and HPA-15a, fol-
lowed by 12 (27.3%) in HPA-15b, and eight (18.2%) in HPA-
3a. In addition, 19 newborns (43.2%) had the heterozygotic
genotype of the particular platelet antigen whereas the
mothers carried the homozygotic genotype (data not
shown). The frequencies of homozygotic mother with het-
erozygotic neonate were 15.9% in both HPA-3a and HPA-
15b, 9.1% in HPA-15a, 6.8% in HPA-3b, and 2.3% in both HPA-2a and HPA-6a.Antibody screen using a commercial ELISA
kit detected maternal HPA antibodies in five samples, but
neonatal HPA discrepancies were only found in HPA-3b,
HPA-15a, and HPA-15b (data not shown). HLA class I anti-
bodies were found in seven mothers and neonatal HPA
discrepancies were same as mentioned previously. The
distribution of mothers with HLA and HPA antibodies were
shown in Table 1 along with their pregnancy experience and
blood type.
Discussion
Providing the HPA distribution data enables the risk pre-
diction of platelet-specific alloimmunization in different
ethnic groups and improves the ability to prepare HPA-
compatible platelet product [16,17]. The HPA frequencies
tallied in this study were mostly in accordance with the
previous research [13], with the exception of the fre-
quencies for HPA-3 and HPA-15, which had approximately
5e10% variations due to the small sample size.
The incompatibility of the platelet antigens between
mothers and their fetuses may cause thrombocytopenia in
the fetuses or neonates as a consequence of fetomaternal
immunization. The most frequent causative factor for NAIT is
HPA-1. According to the research in a Caucasian population,
6e12% of HPA-1a-negative women had anti-HPA-1a devel-
opment associated with HLA-DRB3*0101 [9]. The research in
a Japanese population demonstrated that the antiplatelet
antibodies were found in 0.91% of pregnant women, and
these were mostly alloantibodies of HPA-4 and HPA-5. In
addition, estimated antibody productions were 24% in the
HPA-4b- and 14% in the HPA-5b-negative women [10].
In this study, we found that HPA partial genotyping
mismatch was common, and nearly half of the newborns
28 W.-H. Yang et al.carried the platelet antigen that was absent from their
mothers. However, the platelet antibodies detected from
the maternal plasma samples did not correlate with the
neonatal HPA discrepancies. This may be due to the
different distribution frequencies of HPA in Taiwan and the
antigenicity of HPA-3 and HPA-15. In contrast to the fre-
quency of HPA-1a in Caucasians, the distribution in Taiwan
is almost 100%, making antibody production for the HPA-1
system unlikely. Moreover, the gene frequencies of HPA-4b
and HPA-5b in the Japanese population were higher when
compared to those of the Taiwanese population. Therefore,
the almost unitary presence in HPA-1, HPA-4, and HPA-5
may contribute to the rarity or absence of NAIT cases in
Taiwan.
Furthermore, the most common genetic HPA partial
mismatches were found to be HPA-3b, HPA-15a, and HPA-
15b in this study. Nevertheless, the genetic variations and
high mismatching rate in the HPA-3 system did not result in
the production of anti-HPA-3b antibody. Ghevaert et al.’s
[9] research involving 200 cases of fetomaternal alloim-
mune thrombocytopenia showed that the high-frequency
HPA antibodies were anti-HPA-1a (75%), anti-HPA-5b
(15.5%) and anti-HPA-15b (4%), and that no anti-HPA-3b
was detected. The absence of anti-HPA-3b may be
explained by its weak antigenicity or lability [11,18,19]. In
addition, the HPA-3 system is one of the most diversified
HPA genotypes in Taiwan. However, only a few NAIT cases
were reported in the past as a result of anti-HPA-3a or anti-
HPA-3b [11,20]. Currently, the antigenicity of HPA-3 and its
relationship with NAIT are not clear.
The HPA-15 antibodies have been reported for their
clinical significance in NAIT. The incidence of occurrence in
HPA-15 antibodies was as common as the HPA-5 system an-
tibodies in Caucasian studies [21,22]. Because of the reagent
restriction, HPA-15 antibodies were not being detected.
Therefore, the relationship between the incompatibility of
the HPA-15 system and the production of specific antibody is
unknown. The results shown in Table 1 did not show a cor-
relation between maternal antibody production and preg-
nancy experience and blood type of the mothers.
The results from this study show that maternal-neonatal
HPA mismatch does not necessarily lead to the production
of HPA alloantibodies in the mothers. Additional research is
necessary to understand the production mechanism of HPA
alloantibodies in NAIT.
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